Best of Lipid Forum®: Examining the Role of Lp(a) as a Risk Factor in Atherosclerotic Cardiovascular Disease

Best of Lipid Forum®: Examining the Role of Lp(a) as a Risk Factor in Atherosclerotic Cardiovascular Disease

Lipoprotein(a) [Lp(a)] is a low-density lipoprotein particle that is assoc…

Expiration Date: 4/29/2024

Max Credits: 2

View Activity

Saving the Hearts of Women Through Prevention

Saving the Hearts of Women Through Prevention

Cardiovascular disease (CVD) is the leading cause of death globally, and w…

Expiration Date: 9/29/2023

Max Credits: 2

View Activity

Optimizing LDL-C Reduction with Oral Therapy: Featuring the Wheel of Knowledge Challenge

Optimizing LDL-C Reduction with Oral Therapy: Featuring the Wheel of Knowledge Challenge

In the United States, cardiovascular disease is the leading cause of death…

Expiration Date: 11/4/2022

Max Credits: 0

View Activity

Saving the Hearts of Women Through Prevention

Saving the Hearts of Women Through Prevention

Cardiovascular disease (CVD) is the leading cause of death globally, and w…

Expiration Date: 9/21/2022

Max Credits: 0

View Activity

New Oral Options for Diabetic Dyslipidemia Management

New Oral Options for Diabetic Dyslipidemia Management

Type 2 diabetes mellitus (T2DM) is a major risk factor for cardiovascular …

Expiration Date: 6/29/2021

Max Credits: 0

View Activity

Best of Preventive Cardiology Summit: Applying New Options for Optimal CV Risk Management

Best of Preventive Cardiology Summit: Applying New Options for Optimal CV Risk Management

In the United States, cardiovascular disease (CVD) is the leading cause of…

Expiration Date: 1/20/2021

Max Credits: 0

View Activity

Cardiovascular Risk Reduction With PCSK9 Inhibitors: Evolving Evidence, Recommendations, and Controversies

Cardiovascular Risk Reduction With PCSK9 Inhibitors: Evolving Evidence, Recommendations, and Controversies

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have prov…

Expiration Date: 7/15/2020

Max Credits: 0

View Activity

Rapid-Fire Roundtable: Addressing Clinical Challenges Regarding the Use of PCSK9 Inhibitors

Rapid-Fire Roundtable: Addressing Clinical Challenges Regarding the Use of PCSK9 Inhibitors

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have prov…

Expiration Date: 1/13/2020

Max Credits: 0

View Activity

Test Your Knowledge in the Use of PCSK9 Inhibitors in the Reduction of CV Risk: A Wheel of Knowledge Challenge

Test Your Knowledge in the Use of PCSK9 Inhibitors in the Reduction of CV Risk: A Wheel of Knowledge Challenge

As clinical data emerge regarding the benefit of proprotein convertase sub…

Expiration Date: 1/9/2020

Max Credits: 0

View Activity

Advancing Science in Residual Cardiovascular Risk: Will New Cardiovascular Outcomes Trials Bring a Paradigm Shift in Patient Care?

Advancing Science in Residual Cardiovascular Risk: Will New Cardiovascular Outcomes Trials Bring a Paradigm Shift in Patient Care?

Despite therapeutic advances, cardiovascular disease (CVD) continues to be…

Expiration Date: 1/3/2020

Max Credits: 0

View Activity